Literature DB >> 7518352

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

A Takahashi1, H Sasaki, S J Kim, K Tobisu, T Kakizoe, T Tsukamoto, Y Kumamoto, T Sugimura, M Terada.   

Abstract

The presence of mRNAs for vascular endothelial growth factor (VEGF) and a VEGF-related protein, placenta growth factor (PIGF) was examined in 29 cases of renal cell carcinoma tissues and adjacent normal kidney tissues and in 4 human renal cell carcinoma cell lines. Northern blot analysis showed that 26 of 27 hypervascular renal cell carcinoma tissues (96%) exhibited a markedly elevated level (3-13 fold) of VEGF mRNA compared to the adjacent normal kidney tissues. Even tumors of small size, whenever they were hypervascular, overexpressed VEGF mRNA. We also demonstrated that mRNA for PIGF was expressed in 21 of 23 hypervascular renal cell carcinoma tissues (91%) but was not detected in the adjacent normal kidney tissues. Two hypovascular carcinoma tissues neither overexpressed VEGF mRNA nor had PIGF mRNA. VEGF mRNA was detected in four human renal cell carcinoma cell lines, while PIGF mRNA was not. There was no difference in the level of basic fibroblast growth factor mRNA between tumor tissues and normal kidney tissue, although our previous study demonstrated elevated basic fibroblast growth factor protein in the serum of renal cell carcinoma patients (K. Fujimoto et al., Biochem. Biophys. Res. Commun., 180: 386-392, 1991). Taken together, these results suggest that VEGF, PIGF, and basic fibroblast growth factor are cooperatively working to increase the angiogenesis in renal cell carcinoma in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518352

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  88 in total

1.  Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Authors:  M Takahashi; D R Rhodes; K A Furge; H Kanayama ; S Kagawa; B B Haab; B T Teh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

Review 5.  Multifaceted role of Rho proteins in angiogenesis.

Authors:  Sofia D Merajver; Saad Z Usmani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

6.  Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.

Authors:  Zanfeng Wang; Tingwei Liu
Journal:  Mol Cell Biochem       Date:  2017-08-31       Impact factor: 3.396

7.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 8.  Molecular basis for the treatment of renal cell carcinoma.

Authors:  Cristina Suárez; Rafael Morales; Eva Muñoz; Jordi Rodón; Claudia M Valverde; Joan Carles
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

9.  Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Authors:  Martin G Klatt; Daniel J Kowalewski; Heiko Schuster; Moreno Di Marco; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

10.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Authors:  Henry Q Xiong; Roy Herbst; Silvana C Faria; Catherine Scholz; Darren Davis; Edward F Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp Arthur Charnsangavej; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.